Effects of nifedipine and diltiazem on hemodynamic responses at rest and during exercise in hypertensive patients.

Yamakado, Tetsu; Oonishi, Noriyoshi; Nakano, Takeshi; Takezawa, Hideo

doi:10.1253/jcj.49.415

Cited by 6 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral administration of diltiazem 240 to 360 mg/ day in divided doses effectively decreased supine blood pressure in patients with mild to moderate hypertension (Amodeo et al 1986;Lewis et al 1985;Pool et al 1985); similar results have been ob-tained with controlled-release formulations administered once daily (Felicetta et al 1992;Massie et al 1992) and in Japanese patients given a 180 mg/ day dosage (Yamakado et al 1985;Yamauchi et al 1986). Several studies have shown controlledrelease diltiazem to effectively control blood pressure over 24 hours (Kelly et al 1991;Massie et al 1992;Whelton et al 1992).…”

Section: Patients With Systemic Hypertensionmentioning

confidence: 77%

Diltiazem

Markham¹,

Brogden²

1993

Drugs & Aging

View full text Add to dashboard Cite

Diltiazem is a benzothiazepine derivative calcium antagonist available in several formulations, some of which enable once daily administration. The drug as monotherapy has demonstrated similar efficacy to diuretics in older patients with hypertension. Data comparing diltiazem with beta-blockers and angiotensin converting enzyme inhibitors are more limited, but available studies suggest at least comparable antihypertensive efficacy. Diltiazem as monotherapy or in combination with a beta-adrenoceptor-antagonist, isosorbide dinitrate, or another calcium antagonist, has demonstrated efficacy in patients with effort angina. The drug has also been used intravenously to terminate supraventricular tachycardias and to control the ventricular response to atrial fibrillation or flutter; it also appears to reduce the rate of early reinfarction in patients with non-Q-wave myocardial infarction. The most common adverse events during diltiazem therapy include headache, flushing, peripheral oedema and hypotension. Atrioventricular block although rare, is the most frequent serious adverse event related to diltiazem therapy and may be exacerbated by coadministration of beta-adrenoceptor antagonists, especially in the elderly. Thus, diltiazem appears to be an effective and well tolerated treatment for hypertension and angina in older patients and has shown promise as therapy for supraventricular tachycardias and as prophylaxis against early reinfarction in patients with non-Q-wave myocardial infarction.

show abstract